Ann: Sirtex Records Underlying Full Year NPAT of $42.4 Million, page-34

You have to remember that this is a very heavily manipulated and shorted stock. Its volatility attracts the professional traders. Really, for the past couple of years its been a stock to just trade.

I had hoped things might turn out differently this time, but cancer is trickier to treat than people imagined. Now its a longer haul back to respectability, and hopefully the litigation shambles will turn out to be a distraction rather than a seroius problem. Fundamentally, the company looks like it could offer solid returns from here over the next couple of years.